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Abstract
Mainly because of the large number of people affected and associated significant health policy implications, the Robert 
Koch Institute (RKI) is developing a public health surveillance system using diabetes as an example. In a first step to 
ensure long-term and comparable data collection and establish efficient surveillance structures, the RKI has defined a 
set of relevant indicators for diabetes surveillance. An extensive review of the available literature followed by a structured 
process of consensus provided the basis for a harmonised set of 30 core and 10 supplementary indicators. They correspond 
to the following four fields of activity: (1) reducing diabetes risk, (2) improving diabetes early detection and treatment, 
(3) reducing diabetes complications, (4) reducing the disease burden and overall costs of the disease. In future, in
addition to the primary data provided by RKI health monitoring diabetes surveillance needs to also consider the results
from secondary data sources. Currently, barriers to accessing this data remain, which will have to be overcome, and gaps
in the data closed. The RKI intentends to continuously update this set of indicators and at some point apply it also to
further chronic diseases with high public health relevance.
 PUBLIC HEALTH · SURVEILLANCE · DIABETES MELLITUS · INDICATORS · NCD
1. Background
Public health surveillance is the systematic collection and 
analysis of relevant health data for the provision of up-to-
date information and therefore provides an important basis 
for decisions by diverse (health) political stakeholders to 
protect and improve the health of the population [1-3]. 
Surveillance consequently is one of the key fields of public 
health [4] and is no longer limited merely to infectious dis-
eases. In the 21st century, preventing chronic, noncommu-
nicable diseases (NCD) and providing care to patients has 
become one of the great health challenges globally [5-7]. 
Cardiovascular diseases, cancer, chronic lung diseases and 
diabetes mellitus [8] are now ailments faced not only by 
wealthy countries, but increasingly and significantly also 
contribute to premature mortality in low and middle income 
countries, which has caused the World Health Organiza-
tion (WHO) to define clear goals in its Global Action Plan 
2013-2020 on NCD prevention and control.
Diabetes mellitus in particular has become a serious 
issue for healthcare systems globally [9-11]. Due to high 
incidence rates and the great potential offered by preven-
tion measures, type 2 diabetes is currently a focus. The 
known type 2 diabetes risk factors specifically include 
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istered since the end of the 1990s [23]. Notwithstanding the 
advances in early detection and treatment, diabetes melli-
tus continues to entail severe complications in many 
patients mainly due to the damages to small and large blood 
vessels, as well as the peripheral and autonomic nervous 
system. Cardiac insufficiency, infarction and stroke, diabetic 
foot and amputations of the lower extremities, diabetic eye 
diseases and blindness, renal insufficiency and dialysis, as 
well as diabetic neuropathy are among the most frequent 
complications of diabetes mellitus. Furthermore, in women, 
diabetes increases the risk for complications during preg-
nancy [24], as well as for depression and possibly dementia 
[25] and is associated with an increased risk for certain types
of cancer [26]. Overall mortality for adults with diabetes
remains significantly higher than for people of the same
age without diabetes, although the diabetes-related excess
mortality varies depending on age and gender [9, 27, 28].
This explains the central role played by diabetes melli-
tus as an NCD [19] and why the RKI, on behalf of the Fed-
eral Ministry of Health, chose diabetes as a model disease 
for developing an NCD public health surveillance. Public 
health surveillance [19] requires a scientific framework con-
cept with defined goals and fields of activity, evidence-based 
and health politically relevant indicators [29-32], as well as 
an integration into the established health information sys-
tems [33]. This has not yet been achieved in Germany. While 
the indicator set of the federal states' health reporting [34] 
by default includes indicators to account for diabetes- 
related hospital admissions, early retirements and deaths, 
not all federal states so far have implemented this set of 
indicators. Some states have additional indicators that 
cover, for example, outpatient care. Moreover, some federal 
obesity, lack of physical activity, unhealthy diet, smoking, 
stress and social deprivation [12]. However, the role played 
by environmental and psycho-social factors in type 2 dia-
betes is still not fully understood [13, 14]. Equally, the com-
plex interactions between inherited and acquired risk fac-
tors over the course of a person’s life necessitate further 
research. During gestation and infancy epigenetic mecha-
nisms possibly leave their mark on metabolic processes 
later in life [15]. Gestational diabetes potentially plays a par-
ticularly important role here. Although in most cases 
women recover from this form of diabetes after pregnancy, 
the disease is related to a greater risk of complications dur-
ing pregnancy as well as an increased risk for both the 
mother and the baby to develop type 2 diabetes at a later 
stage in life [16-18].
Importantly, the life-style related risk factors for type 2 
diabetes also play a key role in other important NCDs [5, 19]. 
Often, the large socio-economic implications of type 2 dia-
betes mean that the great public health relevance of type 1 
diabetes, which is a far rarer form and an autoimmune dis-
ease, is also often overlooked. Mostly, this form develops 
at childhood or adolescent age and requires patients to take 
insulin for the rest of their life, with a correspondingly severe 
impact on their quality of life. Moreover, over the past 
decade a so far unexplained global increase in the number 
of new cases of type 1 diabetes is recognised [20, 21].
According to data from the Robert Koch Institute (RKI), 
an estimated 6.7 million adults in Germany are affected by 
diagnosed or undiagnosed diabetes [22, 23]. For adults in 
Germany, the data from national health monitoring sug-
gests that around one in five cases of diabetes goes unrec-
ognised, with a significant decrease in this figure being reg-
Due to the high social  
relevance of diabetes  
and its sequelae, the  
Robert Koch Institute  
has started to establish  
a national diabetes   
surveillance system.
Journal of Health Monitoring
Journal of Health Monitoring 2018 3(S3)
CONCEPTS & METHODSSelecting and defining indicators for diabetes surveillance in Germany
5
systems of the Organisation for Economic Cooperation 
and Development (OECD), the European Union (European 
Community Health Indicators and Monitoring, ECHI) and 
the World Health Organization (WHO) [30, 32, 40]. A fur-
ther focus were indicator-based scientific publications, 
reports and online information systems on diabetes mel-
litus and NCDs in OECD member states. The search con-
sidered publications regardless of date of publication, but 
was limited to publications and information in either Ger-
man or English. For Germany, the health reporting, preven-
tion, rehabilitation and social medicine working group of 
the Permanent Working Group of the Highest State Health 
Authorities (AOLG) in addition identified indicator-based, 
federal state level reports and publications on diabetes 
mellitus. Furthermore, a working group of experts from 
Baden-Württemberg proposed an initial indicator set [41]. 
Moreover, current national and selected international dia-
betes mellitus treatment guidelines [42, 43], cardiovascular 
disease prevention guidelines [44], as well as the quality 
targets of the type 1 and type 2 diabetes disease manage-
ment programmes (DMP) were reviewed [45]. 
The scope of indicators considered was limited per defi-
nition to: (1) indicators on type 1 and type 2 diabetes, as 
well as gestational diabetes, (2) indicators related to one 
of the four defined fields of diabetes surveillance in Ger-
many, (3) indicators defined in either German or English. 
Indicators were excluded if they fell into one of the fol-
lowing categories: (1) indicators for rare forms of diabe-
tes mellitus, (2) indicators for only specific target groups 
(such as patients with particular accompanying diseases), 
(3) and indicators that are not fully compatible with 
Germany’s healthcare system.
states have already published reports on diabetes [35]. No 
federal state has so far established a global concept for 
diabetes surveillance [36]. Besides reviewing, analysing and 
gathering available sources of data, establishing diabetes 
surveillance in Germany will depend primarily on develop-
ing a corresponding scientific framework concept and 
selecting suitable indicators [37].
Following Germany’s 2003 national health target Diabe-
tes mellitus type 2 [38, 39], four fields of activity were iden-
tified: (1) reducing diabetes risk, (2) improving diabetes early 
detection and treatment, (3) reducing diabetes complica-
tions, (4) reducing the disease burden and overall costs of 
the disease [37]. The focus of this article is the methodolog-
ical approach, which the RKI applied to select and define its 
set of indicators for diabetes surveillance in Germany.
2. Methods
The selection and definition of indicators relevant to health 
policy for diabetes was a multi-stage process, which was 
based on two independent reviews of the literature, as well 
as a structured consensus process that involved a nation-
al and international level interdisciplinary panel of experts 
(Annex Table 1).
2.1  Review of the literature
Diabetes mellitus and NCD indicators
Regarding diabetes mellitus and NCDs, the RKI conducted 
a selective review of publications and information systems 
at the population level between January and June 2016. The 
search covered the current international health indicator 
Surveillance systems  
require indicators that are 
evidence-based and 
consented among  
relevant stakeholders.
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tests, rehabilitation, patient satisfaction, avoidable hospi-
tal admissions, screenings (gestational diabetes) and dis-
ease burden. 
To ensure international compatibility, a national and 
international panel of experts conducted a structured 
assessment of the indicators provided by the RKI (Annex 
Table 1a); a process, which included a written assessment 
of indicators regarding their relevance to national diabetes 
surveillance. All members of the external panel of experts 
(n=35) received an email with an evaluation template 
attached to assess the relevance of indicators (essential, 
important, additional and negligible) that included blank 
boxes for further comments. The diabetes surveillance 
working group received back 17 assessment forms, which 
represents a 49% response rate. The results of this initial 
assessment were prepared in the run-up to an international 
scientific workshop at the RKI in July 2016 and then dis-
cussed and finalised during the workshop [37, 47]. 
The following step consisted of evaluating the health 
policy relevance of the selected indicators for diabetes 
surveil lance in Germany. This was based on a two-tier 
Delphi method, which drew on the approach financed and 
started by the EU in the Joint Action on Chronic Diseases 
[48] programme, as well as the RAND/UCLA Appropriate-
ness Method (RAM) [49]. 
In a first step, based on a nine-step scale, the 20 mem-
bers of the diabetes surveillance scientific board (Annex 
Table 1b) were asked to rank all of the indicators according 
to their relevance for health policy. The members of the 
board received a corresponding assessment form as an 
email attachment and asked to return it to the RKI. The 
form permitted them to comment on the clarity, health 
Quality indicators for type 2 diabetes care
A joint scientific cooperation project on diabetes surveil-
lance [46], which was guided by the Institute for Applied 
Quality Improvement and Research in Health Care GmbH 
(aQua) in Göttingen, conducted an additional systematic 
review of the literature with a focus on type 2 diabetes and 
quality of care.
This review was conducted in the literature databases 
of Embase, Medline and the Cochrane Library, as well as 
in the indicator databases of the US Agency for Healthcare 
Research and Quality (AHRQ) and the British Health and 
Social Care Information Centre (HSCIC). Further interna-
tional institutions and agencies that develop, compile or 
publish indicators were also reviewed. To take account of 
the German context, a partially automated text search was 
conducted of Germany’s national guidelines (NVL) on dia-
betes treatment [43].
The following inclusion criteria were defined: (1) indica-
tors for adults with type 2 diabetes, (2) indicators defined 
in either German or English.
The criteria to exclude indicators were defined as: 
(1) indicators that are incompatible with the German health 
system, (2) indicators without clearly defined numerators 
and denominators, (3) indicators that relate exclusively to 
the care aspects of diabetes in certain population groups 
(e.g. African Americans in the USA). 
2.2 Selecting and assessing indicators
At the RKI, the diabetes surveillance working group reviewed 
all of the indicators identified based on these parameters 
and supplemented them with indicators for: diabetes risk 
Journal of Health Monitoring
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ing the discussion, all board members were asked to rate 
once again the indicators regarding their relevance for dia-
betes surveillance in writing and anonymously. The format 
of the assessment forms and evaluation criteria was iden-
tical to that of the first step of the procedure. 
In a separate move, an additional panel of experts pro-
vided an evaluation of the indicators of the cooperation 
project on type 2 diabetes quality of care (Annex Table 1c). 
Here too, the evaluation of indicators was based on a two-
tier Delphi method with a focus on type 2 diabetes quality 
of care. This was based on a modified RAND-UCLA appro-
priateness method (RAM) provided by the aQua institute 
[49, 50]. Relevance in this case too was assessed using 
the nine-step scale described in Figure 1. Both stages of 
the assessment procedure were conducted in writing and 
anony mously and included both filling out an online eval-
uation and an evaluation provided during a face-to-face 
meeting following a discussion of the results of the online 
evaluation.
For a final selection of indicators, the RKI evaluated the 
results from these review strategies. Initially, indicators 
from both indicator sets, which were rated as either highly 
relevant or relevant became part of the final selection and 
indicators with a medium or low relevance rating were 
excluded. In addition, from the indicators provided by the 
cooperation project those considering only specific aspects 
of treatment (such as amputations without vascular pro-
cedures, major amputations without a second opinion pro-
cedure) were also excluded. The remaining indicators were 
grouped into core and supplementary indicators for diabe-
tes surveillance in Germany at the population level based 
on the following criteria: 
political influenceability and international comparability of 
indicators. The RKI received 13 assessment forms back, 
which represents a 65% response rate. Subsequently these 
forms were evaluated and the results for each indicator 
comprehensively prepared: 
   Indicators were classified as highly relevant if they 
received at least 75% from the top three grades (7-9).
   Indicators were classified as relevant if they received 
between 50% and under 75% of ratings from the top 
three grades (7-9).
   Indicators were classified as being of medium relevance 
if at least 50% of ratings were from the medium rates (4-6).
   Indicators were classified as being of low relevance if 
at least 50% of ratings were from the lowest rates (1-3) 
(Figure 1). 
In the second step of the Delphi method, the members 
of the scientific board were invited to a meeting in Berlin. 
16 members participated in the meeting in March 2017, 
which corresponds to an attendance rate of 80%. During 
the meeting the participating board members were pre-
sented with the results of the first assessment round and 
provided with the opportunity to discuss or clarify open 
questions or unclear definitions for each indicator. Follow-
Figure 1 
Evaluation template on indicator selection 
and relevance assessment 
Own diagram
1 2 3 7 8 94 5 6
Low
relevance
Medium
relevance
Highly relevant,
relevant
Journal of Health Monitoring
Journal of Health Monitoring 2018 3(S3)
CONCEPTS & METHODSSelecting and defining indicators for diabetes surveillance in Germany
8
3. Results
Initially, the described search strategy regarding the estab-
lished diabetes and NCD reporting systems served to iden-
tify 32 indicators and/or groups of indicators. In addition, 
13 indicators covering further hitherto insufficiently 
described fields were also adopted. This established an ini-
tial set of 45 indicators.
During the structured consensus process, in an initial 
evaluation round, the international panel of experts assessed 
18 indicators as being ‘essential’, 14 indicators as being 
‘important’, and 8 further indicators as being ‘additional’ 
indicators. Five indicators were rated heterogeneously, no 
consensus was achieved and they could therefore not be 
assigned to one of the categories. No indicator was classi-
fied as ‘negligible’. Furthermore, the members of the dia-
betes surveillance scientific board proposed four additional 
indicators (gestational diabetes prevalence, early retirement, 
hypoglycaemia incidence and information needs). They also 
proposed to split the indicator ‘environmental factors’ into 
three separate indicators (traffic exposure, walkability and 
social deprivation). This produced an indicator set of 51 
indicators. The following national level two-tier Delphi 
method assessed 18 indicators as being highly relevant, 
18 as being relevant and 15 as being of medium relevance. 
No indicator was assessed as being of low relevance.
3.1  Final selection of indicators
The final selection considered only indicators in the highly 
relevant (n=18) and relevant (n=18) groups. This step there-
fore excluded the 15 medium relevance indicators.
Core indicators:
   Indicators classified as highly relevant, regardless as to 
whether they were classified as indicators for type 2 dia-
betes quality of care or not.
   Indicators classified as relevant, which in addition were 
classified as relevant for type 2 diabetes quality of care.
   Indicators classified as relevant for type 2 diabetes qual-
ity of care with a clear link to diabetes surveillance at 
the population level, which had so far not been included 
in the set of indicators used by the diabetes surveillance 
working group.
Supplementary indicators:
   Indicators classified as relevant, which were however 
not identified as indicators for type 2 diabetes quality 
of care.
The consensus-oriented closing discussion round pre-
pared the indicators in line with the ECHI model [51] regard-
ing the following aspects: operationalisation (definition, 
reference population), available stratification variables 
(such as age, gender and socioeconomic status), data avail-
ability, type and periodicity of appropriate data sources, 
scientific background, references, comments on specifici-
ties regarding definition or use. Moreover, indicators were 
pre-assigned to one of the four defined fields of activity in 
line with the 2003 national health target diabetes mellitus 
type 2 [38, 39].
Journal of Health Monitoring
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therapy, diabetic neuropathy, and diabetic foot syndrome). 
Moreover, core and supplementary indicators were defined 
based on the described criteria. The flowchart (Figure 2) 
provides a detailed step-by-step description of the indica-
tors that were identified over the course of the selection 
process. 
During the final step of the procedure, the remaining 
36 indicators were compared to the results of the cooper-
ation project on indicators for type 2 diabetes quality of 
care. Four additional indicators on relevant aspects of dia-
betes treatment were then added to the diabetes surveil-
lance indicator set (age at diagnosis, renal replacement 
Figure 2 
Flowchart diabetes surveillance 
indicator selection 
Own diagram
Review of indicators
- Surveillance diabetes/NCDs -
lndicator set for diabetes 
surveillance: 40 indicators
30 core indicators
10 supplementary indicators
Review of the literature: 32 indicators
lndicators medium relevance (n=15)
Adoption in indicator set: 4 indicators
lndicators specific to the national context or for 
supplementary subject areas (n=13)
lndicators proposed by the scientific board (n=4)
Differentiation of indicator environmental 
factors (n=2 indicators)
Prepared indicator set for international 
assessment: 45 indicators
Assessment: international panel of experts
18 essential indicators
14 important indicators
  8 additional indicators 
  0 negligible indicators
  5 indicators without consensus
    (heterogeneously voted)
Delphi method: scientific board
18 indicators highly relevant 
18 indicators relevant
15 indicators medium relevance
  0 indicators low relevance
▶ Exclusion of duplicates (n=2,613)               
    Exclusion criteria (n=368)
▶ Recap of similar indicators
    prepared indicator set for experts to 
    achieve consensus: 101 indicators 
▶ lndicators considered relevant for 
   diabetes surveillance: 70 indicators
51 indicators
lndicators categorised as highly relevant 
or relevant: 36 indicators
Alignment researched indicators 
(surveillance diabetes/NCD)
Review of the literature and data bases: 
3,498 indicators
Scientific cooperation project
- Quality of care indicators T2D -
NCD: Noncommunicable diseases, T2D: Type 2 diabetes
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tionalisation is available via the internet pages of the RKI 
(www.rki.de/diabsurv). Furthermore, the detailed assess-
ments underlying the selection of indicators is included for 
all indicators as well as their division into core and supple-
mentary indicators (Annex Table 2). 
As a result, the resulting set of 30 core and 10 supple-
mentary indicators/indicator groups for the four fields of 
activity were presented to the scientific board and approved 
in unanimous consensus (Table 1). The complete prepared 
indicator set including information on indicator opera-
(1) Reducing diabetes risk (2) Improving diabetes early detection and treatment
Core indicators Core indicators
Incidence Prevalence of known diabetes
Prevalence gestational diabetes Prevalence of unknown diabetes
Overweight/obesity Disease management programme participation rate
Physical activity Disease management programme quality objectives achievement
Smoking Quality of care
Social deprivation Treatment profiles
Health related quality of life
Screening gestational diabetes
Age at diagnosis
Supplementary indicators Supplementary indicators
Prediabetes Check-up 35
Sugary beverages consumption Patient satisfaction
Absolute diabetes risk (based on the German diabetes risk test)
Contextual factors
(3) Reducing diabetes complications (4) Reducing the disease burden and overall costs of the disease
Core indicators Core indicators
Depression Direct costs
Cardiovascular diseases Hospitalisation rate
Diabetic retinopathy Reduced-earning-capacity pension
Diabetic nephropathy Mortality
Renal replacement therapy Years of life lost
Diabetic (poly-)neuropathy Healthy life years
Diabetic foot syndrome
Amputations related to diabetes
Frequency of severe hypoglycaemia
Supplementary indicators Supplementary indicators
Risk of cardiovascular events Years lived with disability
Complications during pregnancy Disability-adjusted life years (DALYs)
Table 1 
Subject areas for indicators for 
diabetes surveillance in four fields of activity 
Own diagram
Using a multi-stage 
consensus process,  
30 core and 10 supplemen-
tary indicators for  
surveillance were  
consented and assigned  
to four fields of activity.
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models [52]. Furthermore, population representative esti-
mates on quality of life and a comparison of the functional 
limitations faced by adults with and without diabetes mel-
litus are possible, as are estimates on diabetes comorbid-
ity [53] and for selected indicators on the quality of care for 
adults with diabetes mellitus [54]. Secondary sources of 
data often offer in particular the advantage of providing 
information on a large number of cases, the regular avail-
ability of this data and a lack of distortion effects due to 
non-participation. Data from statutory health insurances 
(GKV) for example or the associations of statutory health 
insurance physicians (KVen) provide up to date, periodi-
cally recurrent estimates on the development of the inci-
dence of medically diagnosed diabetes including the pos-
sibility of differentiating between types of diabetes and 
region [55, 56]. An assessment of the quality of care is pos-
sible, based as much on the results of regular DMP analy-
ses [45, 57] as on GKV routine data provided on out and 
inpatient treatment [58, 59]. 
Diabetes surveillance will therefore also need to estab-
lish the specific strengths and weaknesses of each source 
of data. This should also lead to recommendations regard-
ing the use of this data and its application to other diseases 
for a broader surveillance of NCDs in the future. Imple-
mentation of the data transparency act (DaTraV) in par-
ticular, which was begun by the German Institute of Med-
ical Documentation and Information (DIMDI) in 2014, 
meanwhile provides data for morbidity-oriented risk struc-
ture compensation (Morbi-RSA) from all statutory health 
insurers for research. Processing of this data constitutes 
a first and important step towards using routine data for 
surveillance. In spite of providing data for everybody 
Where possible, and depending on the available data, 
the diabetes types are differentiated, and, depending on 
the available data, the results also stratified by age, gender, 
social status, education and region.
4. Discussion and outlook
The selected set of indicators for diabetes surveillance in 
Germany aims to collect detailed, comparable and succes-
sive data on diabetes mellitus in Germany. This should 
establish a firm basis for diabetes surveillance, and aims 
to ensure an up to date and comprehensive analysis of dis-
ease dynamics, potential for prevention and care needs. 
The epidemiologic development of incidence and preva-
lence will be covered, as will the development of the known 
risk factors, associated diseases and quality of care that 
can largely be influenced. What is crucial here is a differ-
entiation by gender, age, socioeconomic status and region. 
This last factor establishes a bridge to federal state level 
health reporting.
In Germany, potentially useful and ample data is already 
available. As each source of data has its specific advantages 
and disadvantages, the described consensually agreed indi-
cator set references different sources of data for calculat-
ing indicators depending on the availability of such data. 
Primary RKI health survey data for example permits an 
analysis stratified by socioeconomic status and further indi-
vidual level aspects, and, by referring to laboratory analysis, 
allows estimating the prevalence of unknown diabetes in 
the population. Furthermore, information on a set of risk 
factors is collected, which facilitate predicting the develop-
ment of a type 2 diabetes by means of established risk 
Data from the nationwide 
health monitoring of the 
Robert Koch Institute and 
routine data will be used for 
continuous data analysis and 
timely reports of results.
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pared for the different target groups (universities, politics, 
patients, the general public etc.). 
In the future, diabetes surveillance should serve as a 
model for a broader surveillance of NCDs, whereby the 
transferability of the model to other diseases still needs to 
be tested. Importantly, the indicator set should not be too 
rigid and developed further. This applies for example to the 
indicators for diabetes-related health competency in the 
overall population and among adults, who already have 
diabetes. Currently, a population representative telephone 
survey on disease knowledge and information needs is 
being conducted by the RKI in close cooperation with Ger-
many’s Federal Centre for Health Education (BZgA). Fur-
thermore, for a surveillance of NCDs, describing social and 
health policy context factors and the implementation of 
measures through indicators will be key. Moreover, the 
indicator system should be continuously further developed 
regarding compatibility with the nascent health informa-
tion systems at the international level (WHO, EU). This 
applies in particular to activity field 1 (reducing diabetes 
risks), which will require the indicator group ‘context fac-
tors’ to be developed. Indicators in activity fields 2 and 3 
(reducing diabetes complications, diabetes early detection 
and treatment) are defined relatively completely as regards 
the current quality target criteria (DMP, St Vincent criteria). 
Minor modifications, however, owing to the continuous 
updating of current definitions must be expected.
Regarding a future broader surveillance of NCDs, the 
goal remains to also define lead indicators analogous to 
the Swiss model over and above the differentiation between 
core and supplementary indicators which have already been 
established [60]. Lead indicators are defined as having an 
insured in the GKV, the data set currently remains limited 
to outpatient and inpatient diagnoses and the outpatient 
provision of medicines. Further data on outpatient services, 
as well as on operations, procedures or general measures 
in inpatient care is not included. Certain process-oriented 
indicators, however, require such information. A satisfac-
tory solution to accessing sources of data that include such 
information (GKV and KV routine data, as well as DMP 
documentation data) is still lacking. Generally, these bod-
ies of data are only accessible in the context of research 
cooperation projects. Surveillance, however, would demand 
a regular access to such sources of data. Clearing these 
obstacles in a dialogue with the holders and users of such 
data is desirable. In addition, the indicators of quality 
deducted from DMP are subject to a certain degree of 
change over time regarding their definition and target 
population (definition of the numerator and denominator 
sample).
To define indicator sets, this process of seeking consen-
sus seems appropriate. Establishing an interdisciplinary 
advisory committee has meant that indicators for relevant 
fields of activity in the areas of public health and preven-
tion as well as medical treatment could be defined. Com-
bining online assessments in writing and consensus- 
oriented discussion rounds during the bi-annual face-to-
face board meetings is evidently a practicable and efficient 
approach. The established indicator set now for the first 
time provides a concept for a German surveillance system 
for one chronic, noncommunicable disease – diabetes mel-
litus. Initial analyses based on these newly established indi-
cators will now begin and health reporting formats will be 
developed to ensure that the results are adequately pre-
The consented set of  
indicators is to be 
continously adapted and  
the methodological  
approach could be applied  
to other noncommunicable 
diseases of high public 
health impact.
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No. Indicator Median Min Max QRange Q1 Q3 Type
Field of activity 1: Reducing diabetes risk
1 Incidence 9 9 9 0 9 9 C
2 Prevalence gestational diabetes 8 1 9 2 8 9 C
3 Prediabetes 8 3 9 3 5 8 S
4 Overweight/obesity 8 5 9 1 7 8 C
5 Physical activity* 7 4 9 3 5 8 C
6 Smoking 8 5 9 1 7 8 C
7 Sugar-sweetened beverages 7 1 9 5 3 8 S
8 Absolute diabetes risk 7 1 8 3 5 8 S
9 Social deprivation 8 1 9 1 7 8 C
10 Contextual factors 7 4 9 2 6 8 S
Metabolic syndrome 5 1 7 3 3 6 M
Traffic load 4 1 6 3 2 5 M
Walkability 6 1 8 3 4 7 M
Perceived versus objective diabetes risk 5 1 9 3 4 7 M
Participation in prevention 4 1 9 4 3 7 M
Field of activity 2: Improving diabetes early detection and treatment
11 Prevalence of known diabetes 9 8 9 0 9 9 C
12 Prevalence of unknown diabetes 8 5 9 1 8 9 C
13 Disease managemant programme participation rate* 7 4 9 2 6 8 C
14 Disease management programme quality objectives achievement 8 6 9 1 7 8 C
15 Quality of care 8 3 9 1 7 8 C
16 Treatment profiles 8 3 9 2 7 9 C
17 Health related quality of life* 8 5 9 3 6 9 C
18 Check-up 35 7 1 8 5 3 8 S
19 Screening gestational diabetes 8 3 9 2 7 9 C
20 Patient satisfaction 7 1 9 5 3 8 S
21 Age at diagnosis** 9 7 9 C
Blood sugar measurement (included in 'quality of care') 5 3 8 4 3 7 M
Medical rehabilitation services use 5 1 9 3 3 6 M
Care at the intersection of rehabilitation and disease management programmes 4 1 9 4 3 7 M
Vaccination 4 1 7 4 2 6 M
Awareness, information needs, treatment preferences 6 1 8 3 5 8 M
Annex Table 2 
Template for consensus on the 
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No. Indicator Median Min Max QRange Q1 Q3 Type
Field of activity 3: Reducing diabetes complications
22 Depression* 8 5 9 2 6 8 C
23 Cardiovascular diseases 9 8 9 1 8 9 C
24 Risk of cardiovascular events 7 1 9 5 3 8 S
25 Diabetic retinopathy 9 7 9 0 9 9 C
26 Diabetic nephropathy 9 7 9 1 8 9 C
27 Renal replacement therapy** 9 7 9 C
28 Diabetic (poly-)neuropathy** 9 7 9 C
29 Diabetic foot syndrome** 9 7 9 C
30 Amputations related to diabetes (OECD indicator) 9 8 9 0 9 9 C
31 Complications during pregnancy 8 3 9 3 6 9 S
32 Frequency of severe hypoglycaemia* 8 1 9 2 6 8 C
Avoidable hospital admissions 6 3 9 3 5 8 M
Field of activity 4: Reducing the disease burden and overall costs of the disease
33 Direct costs* 7 3 9 3 5 8 C
34 Hospitalisation ratea* (OECD indicator) 7 1 8 2 5 7 C
35 Reduced-earning-capacity pension* 7 1 9 3 5 8 C
36 Mortality 9 7 9 0 9 9 C
37 Years of life lost 8 3 9 2 7 9 C
38 Healthy life years 8 3 9 2 7 9 C
39 Years lived with disability 7 1 9 5 3 8 S
40 Disability-adjusted life years 8 2 9 3 5 8 S
Doctors' appointments 5 1 7 3 3 6 M
Days of sick leave 6 1 8 3 4 7 M
Early retirements 5 1 7 1 5 6 M
Indirect costs 6 1 9 2 5 7 M
Evaluation template on indicator selection and relevance assessment (s. Figure 1):           Low relevance             Medium relevance             Highly relevant, relevant
Q: Quantile; Q1: 25% Quantile, Q3: 75% Quantile
C:  Core indicator
S:  Supplementary indicator
M: Indicator of medium relevance (indicators were initially excluded from the final indicator set for diabetes surveillance)
 *   Supplementary indicator that became a core indicator after considering the reviewed indicators for type 2 diabetes care
 ** Adopted in the indicator set for diabetes surveillance after review of type 2 diabetes treatment indicators 
  a   Formerly: days spent in hospital
OECD: Organisation for Economic Co-operation and Development
Bold type: Core indicator 
Annex Table 2 Continuation 
Template for consensus on the 
diabetes surveillance indicator set
Own diagram 
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